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Background: Glycoprotein (GP) IIb/IIIa inhibitors therapy is associated with better outcome in patients with non ST elevation acute coronary 
syndromes (NSTEACS) who undergo an invasive procedure. However the optimal timing of therapy (upstream - at hospital admission and prior 
coronary catheterization, or downstream - after coronary angiography) is still debated. Aim of this meta-analysis was to compare the outcome of 
patients with NSTEACS randomized to upstream versus downstream GP IIb/IIIa inhibitors therapy.
Methods: We scanned the literature from January 1990 to May 2009 to identify all randomized trials comparing upstream administration of Gp 
IIb/IIIa inhibitors versus its downstream use in NSTEACS treated invasively. No language restrictions were enforced. Data were managed according 
to the intention-to-treat principle. Clinical endpoints were death, myocardial infarction, urgent target vessel revascularization, major adverse cardiac 
events (MACE), major bleeding and net adverse clinical events (NACE, ie the composite of MACE and major bleeding) occurring in-hospital, and at 
30 days.
Results: We identified 6 randomized clinical trials but for only 5 of these trials outcome data were available. A total of 9753 patients were 
randomized to upstream GP IIb/IIIa inhibitors therapy compared with 9719 patients randomized to downstream therapy. Upstream therapy was 
associated with reduced in hospital or 30 days MACE (OR 0.9, 95 % CI 0.82-0.99, p=0.03) compared to downstream therapy, without differences in 
mortality (OR 1.04, 95% CI 0.85-1.27, p=0.69). However the risk of major bleeding was significantly higher with upstream therapy (OR 1.35, 95% CI 
1.11-1.64, p=0.002) but without differences in the NACE between the two approaches (OR 1.01, 95% CI 0.93-1.11, p=0.79).
Conclusions: Early administration of GP IIb/IIIa inhibitors in NSTEMI patients is associated with significant reduction in ischemic events compared 
to a selective deferred therapy after coronary angiography. However since upstream therapy is also associated with increased bleeding complications 
this approach might be reserved for patients at low hemorrhagic risk
